Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Restructuring Costs (2023 - 2025)

BioXcel Therapeutics (BTAI) has 3 years of Restructuring Costs data on record, last reported at $194000.0 in Q3 2025.

  • For Q3 2025, Restructuring Costs fell 87.51% year-over-year to $194000.0; the TTM value through Sep 2025 reached $2.6 million, down 60.39%, while the annual FY2024 figure was $2.4 million, 41.36% down from the prior year.
  • Restructuring Costs reached $194000.0 in Q3 2025 per BTAI's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $4.2 million in Q3 2023 and bottomed at $194000.0 in Q3 2025.
  • Average Restructuring Costs over 3 years is $1.7 million, with a median of $1.2 million recorded in 2024.
  • Peak YoY movement for Restructuring Costs: crashed 62.7% in 2024, then plummeted 87.51% in 2025.
  • A 3-year view of Restructuring Costs shows it stood at $4.2 million in 2023, then plummeted by 62.7% to $1.6 million in 2024, then crashed by 87.51% to $194000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Restructuring Costs were $194000.0 in Q3 2025, $1.6 million in Q3 2024, and $856000.0 in Q2 2024.